Clinical Trials List
2025-02-07 - 2032-12-31
Phase I/II
Recruiting8
ICD-10C15.3
Malignant neoplasm of upper third of esophagus
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9150.0
Malignant neoplasm of cervical esophagus
-
-
Trial Applicant
Merck Sharp & Dohme (I.A.) LLC
-
Sponsor
-
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/09/09
Investigators and Locations
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 劉奕廷 無
- Chih-Chieh Yen 無
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Hung-Yuan Yu 無
- 姜乃榕 無
- Chien-An Liu 無
- Yi-Ping Hung 無
- 唐振育 無
- 翁敬堯 無
- Tien-Hua Chen 無
- 陳宥任 無
- 黃宣恩 無
- Chueh-Chuan Yen 無
- Yun-Cheng Hsieh 無
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 王閔宏
- Wang Yao-Kuang
- Jeng-Shiun Du Division of Hematology & Oncology
- Yi-Hsun Chen Digestive System Department
- Tsung-Jang Yeh Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Chia-Chi Lin Division of Hematology & Oncology
- 莊建淮 Division of Ophthalmology
- 郭弘揚
- TA-CHEN HUANG
- JHE-CYUAN GUO
- Ta-Ching Chen
The Actual Total Number of Participants Enrolled
0 Recruiting
Study Contacts
- -
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
Exclusion Criteria
The Estimated Number of Participants
-
Taiwan
22 participants
-
Global
298 participants
